secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2026-08-12T20:16:29+00:00
Accession:  0001193125-26-346894
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M
-----------------------------------------------------------------------------

- Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.
- FY2026 revenue guidance raised to $3.75-4.25M from $3-4M, implying ~241-286% YoY growth.
- 21 active commercial cancer centers (+30% from 16 in Q1); 63 in pipeline; Q3 revenue expected to exceed Q2.
- Phase III TIGeR-PaC fully enrolled; 78/86 events; completion H1 2027, topline H2 2027.
- First RenovoCath use in sarcoma patient; cash $9.5M, sufficient into H2 2027; break-even target Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/0001193125-26-346894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/rnxt-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer